February 3, 2017
The Chase Group is pleased to announce another successful leadership recruitment for Esperion Therapeutics with the placement of the Senior Director, Global Regulatory Affairs. This latest addition to the Esperion team was secured and started employment in less than 60 days.
Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid, the Company’s lead product candidate, is a targeted therapy that significantly reduces elevated LDL-C levels in patients with hypercholesterolemia, including those inadequately treated with current lipid-modifying therapies.
For more information on how The Chase Group successfully identifies, recruits, and secures high-caliber talent in this competitive arena, contact Ken Allison at (913) 663.3100 or at ken@chasegroup.com.
